Private company
Who owns Vantage Oncology Holdings, LLC
One company in the researched set discloses a stake in Vantage Oncology Holdings, LLC, none of it sized by anyone who discloses it. Vantage Oncology Holdings, LLC is private, so no 13F reports it: a 13F covers exchange listed positions only. These figures exist because each holder disclosed the stake in its own filings.
The disclosed stakes
One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.
Where each figure comes from
A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.
- McKesson Corporation. Same combined-balance limitation as ClarusONE: the $395 million (31 Mar 2026) / $380 million (31 Mar 2025) noncontrolling-interest figure covers ClarusONE, Vantage and SCRI Oncology together and is not split by entity, so Vantage's individual value and percentage are not sourceable. Recorded unsized because the investee and McKesson's controlling, consolidating position are named in the filing. source
What this page is not
It is not a complete register. It lists the holders who happen to be inside the researched set and disclosed the stake themselves. A private company can have many other shareholders, and nothing here rules them out: venture investors, founders and employees usually appear in no public filing at all. Percentages are of Vantage Oncology Holdings, LLC where a holder stated one, and are missing where no holder did.